Solel Partners LP: CVS HEALTH CORP (CVS): Quarterly 13F Position History
As of Q1 2026, Solel Partners LP reported 493,700 shares of CVS HEALTH CORP (CVS), worth $35.5M and representing 7.6% of its 13F equity book. Quarter-over-quarter share count change: 100,000 (-16.8%) . The position first appeared in Q2 2024 and has been disclosed across 8 13F-HR filings in Pactolio's tracked window.
- 493,700Shares Held (Latest Filing)
- $35.5MReported Market Value (Latest Filing)
- 7.6%Portfolio Weight (% of 13F Equity Book)
- 100,000Quarter-over-Quarter Share Change
- -$11.7MQuarter-over-Quarter Value Change
- 1,424,400Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 8 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 493,700 | 100,000 | -16.8% | $35.5M | 7.6% | $71.8 |
| Q4 2025 | 593,700 | 120,000 | -16.8% | $47.1M | 7.6% | $79.4 |
| Q3 2025 | 713,700 | +39,400 | +5.8% | $53.8M | 10.4% | $75.4 |
| Q2 2025 | 674,300 | 100,000 | -12.9% | $46.5M | 8.1% | $69.0 |
| Q1 2025 | 774,300 | 650,100 | -45.6% | $52.5M | 9.7% | $67.8 |
| Q4 2024 | 1,424,400 | +295,500 | +26.2% | $63.9M | 12.5% | $44.9 |
| Q3 2024 | 1,128,900 | +625,500 | +124.3% | $71.0M | 13.9% | $62.9 |
| Q2 2024 | 503,400 | — | — | $29.7M | 4.8% | $59.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Solel Partners LP first disclose a CVS position in 13F-HR filings?
Solel Partners LP first reported CVS HEALTH CORP (CVS) on its 13F-HR filing for the period ending 2024-06-30 (Q2 2024). The position has appeared on 8 reported quarters within Pactolio's tracked window.
What was Solel Partners LP's most recent quarter-over-quarter share-count change in CVS?
Between Q4 2025 and Q1 2026, Solel Partners LP reduced its CVS position by 100,000 shares (-16.8%), leaving 493,700 shares at a market value of $35.5M.
Does the implied price-per-share represent Solel Partners LP's cost basis in CVS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.